ⓘ Free online encyclopedia. Did you know? page 89




                                               

Afucosylated monoclonal antibodies

Afucosylated monoclonal antibodies are monoclonal antibodies engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose sugar units. When antibodies are afucosylated the effect is to increase antibody-dependen ...

                                               

Bimekizumab

Bimekizumab is a monoclonal antibody that is being investigated for ankylosing spondylitis and psoriasis. This drug is developed by UCB. In 2018, bimekizumab undergoing phase III clinical trials.

                                               

Bispecific monoclonal antibody

A bispecific monoclonal antibody is an artificial protein that can simultaneously bind to two different types of antigen. BsMabs can be manufactured in several structural formats, and current applications have been explored for cancer immunothera ...

                                               

Camrelizumab

Camrelizumab is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. This drug is developed by Jiangsu HengRui medicine co. LTD. By 2019, camrelizumab undergoing phase II / III cli ...

                                               

Cantuzumab

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen. It is usually associated with one of several cytotoxic agents, obtaining antibody-drug conjugates: Cantuzumab mertansine. ...

                                               

CBR96-doxorubicin immunoconjugate

cBR96-doxorubicin immunoconjugate is an antibody-drug conjugate or directed to the Lewis-Y antigen designed for the treatment of cancer. The payload is the chemotherapy drug doxorubicin which is connected with a hydrazone linker to cysteine resid ...

                                               

Denintuzumab mafodotin

Denintuzumab mafodotin is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F, ...

                                               

Domagrozumab

Domagrozumab is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy. This drug was developed by Pfizer.

                                               

Duvortuxizumab

Duvortuxizumab is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies. This drug was developed by Janssen global services.

                                               

Eldelumab

Eldelumab is a fully human monoclonal antibody that targets chemokine ligand 10 /Interferon-γ-inducible protein-10 designed for the treatment of Crohns disease and ulcerative colitis. This drug developed by Bristol-Myers Squibb and Medarex

                                               

Emactuzumab

Emactuzumab is a humanized monoclonal antibody directed against CSF-1R expressed on macrophages and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients w ...

                                               

Emibetuzumab

Emibetuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC This drug developed by Eli Lilly and company.

                                               

Enfortumab vedotin

Enfortumab vedotin is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug and the linker. The most common side effects are ...

                                               

Enoblituzumab

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators. This drug developed ...

                                               

Evinacumab

Evinacumab is a monoclonal antibody designed for the treatment of dyslipidemia. This drug was developed by Regeneron pharmaceuticals, Inc. In phase 1, first-in-human, ascending single dose, placebo, placebo-controlled, double-blind study evaluate ...

                                               

Fasinumab

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain. This drug was developed in partnership Teva pharmaceutical industries and Regeneron pharmaceuticals. She currently is in phase III clinical trials.

                                               

Fletikumab

Fletikumab is a monoclonal antibody designed for the treatment of rheumatoid arthritis. This drug was developed by Novo Nordisk A / s Novo until he stopped work in inflammation.

                                               

Flotetuzumab

Flotetuzumab is a bispecific antibody designed for the treatment of acute myeloid leukemia. This drug is developed by MacroGenics, Inc. in

                                               

Humanized antibody

Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans. The process of "humanization" is usually applied to monoclonal a ...

                                               

Ianalumab

Ianalumab is a monoclonal antibody that is being investigated for autoimmune hepatitis. This drug is being developed by Novartis. Starting in 2018, ianalumab undergoing phase II / III clinical trials.

                                               

Immune stimulating antibody conjugate

Immune stimulating antibody conjugate is a mAb that conjugates an antibody to an immune-stimulatory agent. They are used in targeting tumors, particularly to turn "cold tumors into hot ones". Immune stimulating antibody conjugates work by activat ...

                                               

Inclacumab

Inclacumab is a human monoclonal antibody designed for the treatment of cardiovascular disease. Antibody outlicensed Roche.

                                               

Inebilizumab

Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. Inebilizumab is currently being tested in a phase 2 study for treating Neuromyelitis Optica Spectrum Disorder. NMOSD is a rare autoi ...

                                               

KRN23

KRN23 is an investigational human monoclonal IgG 1 antibody targeted against the phosphaturic hormone, fibroblast growth factor 23. Initially discovered by Kyowa Hakko Kirin, it is now being developed by Ultragenyx and is currently in Phase III c ...

                                               

Landogrozumab

Landogrozumab is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders. This drug developed by Eli Lilly & Co.

                                               

Lebrikizumab

Lebrikizumab is a humanized monoclonal antibody and an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. The drug was created by Tanox under the name TNX-650, and ...

                                               

Lenvervimab

Lenvervimab is a monoclonal antibody that is being investigated for hepatitis B. This drug is being developed by GK Pharma. Starting in 2018, lenvervimab undergoing phase II / III clinical trials.

                                               

Lenzilumab

Lenzilumab is a humanized monoclonal antibody that targets colony stimulating factor 2 /granulocyte-macrophage colony stimulating factor designed for the treatment of chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. In vitro ...

                                               

Letolizumab

Letolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases. This drug developed by Bristol-Myers Squibb.

                                               

Lifastuzumab vedotin

Lifastuzumab vedotin is a monoclonal antibody designed for the treatment of cancer. This drug developed by Genentech / Roche.

                                               

Ligelizumab

Ligelizumab is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It binds to IGHE an acts as an immunomodulator. This drug developed by Novartis Pharma AG. In 2018, ligelizumab undergoi ...

                                               

Lulizumab pegol

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases. This drug developed by Bristol-Myers Squibb.

                                               

Lumretuzumab

Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer. This drug developed by Genentech / Roche.

                                               

Mirikizumab

Mirikizumab is a human monoclonal antibody designed for the treatment of psoriasis. This drug was developed by Eli Lilly and Co. In 2018, mirikizumab undergoing phase III clinical trials.

                                               

Ocaratuzumab

Ocaratuzumab is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders. The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytot ...

                                               

Oleclumab

Oleclumab is a human monoclonal antibody designed for the treatment of pancreatic and colorectal and other cancers. This drug was developed by MedImmune / AstraZeneca.

                                               

Opicinumab

Opicinumab is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis, and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, know ...

                                               

Otlertuzumab

Otlertuzumab is a humanized monoclonal antibody designed for the treatment of cancer. This drug developed by emergent Biosolutions in clinical trials for lymphomas and chronic lymphocytic leukemia CLL

                                               

Pamrevlumab

Pamrevlumab is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. This drug developed by FibroGen, Inc. in

                                               

Perakizumab

Perakizumab is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator. This drug developed by Genentech / Roche.

                                               

Pinatuzumab vedotin

Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies. This drug developed by Genentech / Roche.

                                               

Placulumab

Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. This drug was developed by Teva pharmaceutical industries, Inc. As of 2012, development placulumab was discontinued.

                                               

Plozalizumab

Plozalizumab is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency. This drug developed by Takeda international cooperation.

                                               

Polatuzumab vedotin

Polatuzumab vedotin is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination w ...

                                               

Ravulizumab

Ravulizumab is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This drug developed by Alexion pharmaceuticals, Inc. in It was approved by the U.S. food and ...

                                               

Refanezumab

Refanezumab is a monoclonal antibody designed for the recovery of motor function after stroke. This drug was developed by GlaxoSmithKline.

                                               

Relatlimab

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. This drug is being developed by Bristol-Myers Squibb. Starting in 2018, relatlimab undergoing phase II / III clinical trials.

                                               

Rinucumab

Rinucumab is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration. This drug was developed by Regeneron pharmaceuticals, Inc. in

                                               

Rosmantuzumab

Rosmantuzumab is a humanized monoclonal antibody designed for the treatment of cancer. This drug developed by OncoMed pharmaceuticals.

                                               

Rovelizumab

Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock. The drug is a monoclona ...